Jason Harris


Breast Cancer Survivors Need More Tailored Follow-Up Care

May 7th 2021

Post-treatment care for breast cancer survivors must be personalized to address each survivor’s unique experiences.

Apalutamide Maintains OS Benefit in Castration-Sensitive Prostate Cancer

April 26th 2021

Apalutamide plus androgen deprivation therapy maintained an overall survival advantage over placebo for a broad population of patients with metastatic castration-sensitive prostate cancer after nearly 4 years of median follow-up.

A Desire to Be a Healer Drives Breast Cancer Expert Forward

April 23rd 2021

Sara A. Hurvitz, MD, can remember the exact moment she decided to become an oncologist. It was her first day at the University of Southern California School of Medicine, which she had entered in 1995 without a firm idea of what discipline she wanted to pursue.

TAS-117 Shows Limited Efficacy in Ovarian, Breast Tumors

April 11th 2021

Treatment with TAS-117, a highly potent and selective oral allosteric pan-v-akt murine thymoma viral oncogene homolog inhibitor, demonstrated some clinical efficacy in patients with ovarian cancer harboring PIK3CA E545K mutations and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.

Clinical Benefit of Ripretinib Expands as Investigators Consider Future Directions

April 8th 2021

Encouraging efficacy data for ripretinib as a later-line therapy for patients with advanced gastrointestinal stromal tumor have investigators hypothesizing new approaches to derive even greater benefit with the agent.

Burst of Treatment Options in HCC Complicates Sequencing Decisions

March 27th 2021

Options for systemic treatment for patients with hepatocellular carcinoma have significantly expanded since 2017, when the sole available option was sorafenib. Now, the arsenal includes checkpoint inhibitors, targeted therapies, and combinations of both classes of drugs.

Pandemic Causes Drop in New Oncology Trials, But the Tide May Be Turning

March 18th 2021

The coronavirus 2019 pandemic caused a 60% drop in the initiation of new clinical trials for anticancer therapies compared with prior years.

PARP Inhibitors, Novel Combos Represent the Future in Metastatic CRPC

March 16th 2021

PARP inhibitors and novel combinations targeting the androgen receptor will help define the future treatment paradigm for patients with metastatic castration-resistant prostate cancer.

GI Cancer Expert Is Searching for Big Leaps in Care

March 12th 2021

John L. Marshall, MD, has made it his mission to improve the lives of patients with GI cancers through innovative research, personalized medicine, and focused advocacy.

Trastuzumab Deruxtecan Enters Treatment Paradigm for Gastrointestinal Cancer Subtypes

March 9th 2021

Trastuzumab deruxtecan represents a potential new standard of care for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.